Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. easiviral

EASIVIRAL SIGNED

EASIVIRAL

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 EASIVIRAL project word cloud

Explore the words cloud of the EASIVIRAL project. It provides you a very rough idea of what is the project "EASIVIRAL" about.

simultaneous    stated    care    received    detection    load    trl    cumulative    enhances    critical    combo    gt    capacity    portability    ceo    crisis    share    supply    diagnoses    grow    patient    mins    seal    partners    region    techniques    76    displace    virus    2015    accuracy    sme    diagnostics    30    disrupt    rt    portable    hepatitis    2016    local    prescription    accelerated    improvements    2024    12    granted    blood    viral    decades    proven    made    viruses    urges    september    vl    therapy    acceptance    see    elimination    exists    disruptive    laboratories    ltd    create    detect    robustness    jobs    commercialise    outcomes    operated    intervention    patents    reagents    structure    saving    clinics    threshold    hiv    venture    exceeded    clinical    innovative    excellence    point    offers    altratech    easiviral    battery    innovations    210m    significantly    ebitda    1b    stops    alone    pcr    competitiveness    purify    combination    portfolio    phc    refrigerated    capture    kit    time    labs    revenues    biotechnologies    life    manufacturing    centered    format    market    solution    spread    biomarkers    people    successful    poc    75    18m    feasibility   

Project "EASIVIRAL" data sheet

The following table provides information about the project.

Coordinator		 ALTRATECH LIMITED 

Organization address
address: 4TH FLOOR 103/104 O CONNELL STREET
city: LIMERICK
postcode: V94 AT85
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Ireland [IE]
 Project website http://www.easiviral.com
 Total cost 2˙969˙000 €
 EC max contribution 2˙969˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALTRATECH LIMITED IE (LIMERICK) coordinator 2˙969˙000.00

Map

 Project objective

In September 2016 WHO-Europe stated “Europe is at a critical point with HIV. New diagnoses in the European Region recently increased by 76%”. WHO urges “an accelerated people-centered response” based on taking HIV viral-load (VL) testing out of labs and into local clinics where it is most needed at point-of-care (PoC). No such solution exists today. New disruptive innovations are needed to address this. AltraTech Ltd has developed three proven biotechnologies to capture, purify, and detect the HIV virus from a blood sample, in 40 mins, using proven HIV biomarkers. This enables life-saving clinical intervention, immediate prescription and therapy for the patient, and stops further spread of the virus. The three techniques are innovative. Their combination, in a portable battery-operated kit format, is disruptive. It offers the unique combination of portability, robustness, reduced cost, with simultaneous increase in accuracy, combo-detection of Hepatitis and other viruses, and elimination of refrigerated reagents. It will address the above crisis, the HIV-VL PoC market, and has the potential to disrupt the €1B viral clinical diagnostics market and displace RT-PCR diagnostics that have been used in laboratories for two decades. Following a successful SME-Phase-1 feasibility, the technology received a Seal-of-Excellence in Phase-2(PHC-12-2015) – exceeded funding threshold. TRL improvements have been made in 2016, and a new CEO, management structure, and new venture funding significantly enhances AltraTech capacity to commercialise EASIVIRAL and see it reach market acceptance. The outcomes will enable capture a market leading share of > 30% of the €210M PoC HIV-VL market, reach cumulative EBITDA for this product alone of more than €18M by 2024. AltraTech will create 75 new jobs during this time, grow its portfolio of granted patents on its disruptive EASIVIRAL technology, and increase the revenues, jobs, and competitiveness of its manufacturing supply partners

 Deliverables

List of deliverables.
1000 fabricated silicon sensor chips Demonstrators, pilots, prototypes 2020-02-12 16:28:30
Poster showing lower-limit of quantification Websites, patent fillings, videos etc. 2020-02-12 16:28:31
Data Sheets, App Notes, White Papers, Publicity material Websites, patent fillings, videos etc. 2020-01-30 10:06:41

Take a look to the deliverables list in detail:  detailed list of EASIVIRAL deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EASIVIRAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EASIVIRAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More